# A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)

> **NCT04089163** · PHASE1 · WITHDRAWN · sponsor: **Tocagen Inc.**

## Conditions studied

- Bladder Cancer

## Interventions

- **BIOLOGICAL:** Toca 511
- **DRUG:** Toca FC (extended-release formulation of flucytosine)

## Key facts

- **NCT ID:** NCT04089163
- **Lead sponsor:** Tocagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12
- **Primary completion:** 2022-01
- **Final completion:** 2027-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision.
- **Last updated:** 2020-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04089163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04089163, "A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04089163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*